Formulation
Powder and solvent for oral solution, developed to support practical preparation and administration.
Science & evidence
Evidence around formulation, pharmacokinetics and the emergency-care pathway.
A concise overview of the science behind Coxor® and the broader clinical context relevant to its development.
The rationale
Early treatment is central to the emergency-care pathway.
Coxor® has been developed for a setting where the timing and practical delivery of established treatment options are important considerations.
This section brings together a carefully reviewed evidence base for healthcare professionals, partners and other qualified stakeholders.
Pharmacokinetics
Development work has examined the absorption profile of Coxor® compared with conventional ASA formats.
Clinical context
The product has been developed for an emergency-care setting and should be understood in the context of approved product information.
Study snapshot
What the Coxor® study does — and does not — show.
The published study was a randomized, open-label, two-arm crossover study in healthy subjects. It compared a 300 mg oral aspirin solution with a single solid aspirin tablet that was chewed and swallowed with 150 mL of water.
The primary focus was pharmacokinetics: the exposure profile of acetylsalicylic acid and salicylic acid after administration.
| Condition | Coxor® oral solution | Chewed tablet |
|---|---|---|
| Fasted, 3 minutes | 356 ng/mL | 204 ng/mL |
| Fed, 3 minutes | 299 ng/mL | 139 ng/mL |
Interpretation boundary
Read the full publicationThe study assessed pharmacokinetic concentrations in healthy subjects. It was not designed to demonstrate clinical outcome benefit, reduced mortality or improved outcomes in patients with acute myocardial infarction.
Selected references
Publicly available research and clinical context.
2022
Peer-reviewed publication of the Coxor® study. View PubMed record
2002
Barbash et al. examined the association between pre-hospital aspirin administration and outcomes in 922 patients with acute myocardial infarction. View PubMed record
1988
ISIS-2 reported on the role of ASA in suspected acute myocardial infarction. View PubMed record
Professional information
Medical and regulatory content must be precise.
Asamedic is building a structured professional resource covering product information, publications, regulatory documentation and approved market materials.
Request professional information